RecruitingNot ApplicableNCT07153627
Rectal Ozone as Neuroprotector Post CNS Insult in Children
Sponsor
Al-Azhar University
Enrollment
120 participants
Start Date
May 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the efficacy of rectal ozone therapy as a neuroprotective modality in Pediatric acquired brain injury.
Eligibility
Min Age: 1 MonthMax Age: 18 Years
Inclusion Criteria5
- Age from 1 month to 18 years.
- Both sexes.
- Children admitted to the pediatric intensive care unit (PICU) with acquired neurological insult.
- Children with neurological sequelae
- Children who are exposed to acquired brain injury, e.g., traumatic brain injury, cardiac arrest, intracranial hemorrhage, central nervous system infections, stroke, tumor, or hypoxia, with neurological sequelae diagnosed by neurological examination and magnetic resonance imaging (MRI), to detect that disorder early.
Exclusion Criteria5
- Patients with no degree of disability or sequelae.
- Patients not fit for Rectal ozone therapy.
- Patients with active epilepsy and recurrent seizures.
- Children with a positive family history of degenerative brain insults.
- Children with behavioral problems.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERRectal ozone sessions
Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
OTHERConventional rehabilitation program
Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07153627
Related Trials
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283178 locations
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT070438941 location
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
NCT069267511 location
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
NCT067614171 location
Comparing Game-Based Reward Systems to Support Children's Engagement:
NCT075094891 location